Figure 3.

Recognition patterns of the selected T-cell clones recognizing PRAME or CTCFL positive tumor cells, without substantial peptide or HLA cross-reactivity. Recognition patterns based on IFN-γ production (ng/mL) after overnight coculture assays with (A) PRAME or CTCFL positive tumor cell lines, (B) PRAME or CTCFL-negative tumor cell lines and healthy cell subsets, and (C) 25 EBV-LCLs, expressing all HLA alleles with an allele frequency ≥ 1% present in the Caucasian population. The HLA allele in (C) is depicted if an HLA allele is recognized by the T-cell clone, meeting the requirement that all EBV-LCLs with this HLA allele are recognized. All cell lines in (A, B) express the HLA allele that presents the targeted peptide, either wildtype or the HLA allele was introduced by transduction (+A2, +A24 or +B7). Percentage relative PRAME or CTCFL expression is depicted, as determined by qPCR. Bars represent mean and symbols depict technical duplicates. (EBV-LCL: Epstein-Barr virus transformed lymphoblastoid cell lines).